Genmab (GE91) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GE91 Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Genmab

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GE91 Stock 12 Month Forecast

Average Price Target

€82.59

▲(182.86% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Genmab in the last 3 months. The average price target is €82.59 with a high forecast of €321.11 and a low forecast of €30.53. The average price target represents a 182.86% change from the last price of €29.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"€20","171":"€171","322":"€322","95.5":"€95.5","246.5":"€246.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":321.105263800104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€321.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82.59488496668399,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€82.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.53120805,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€30.53</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,95.5,171,246.5,322],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.4,50.915789523084925,73.43157904616984,95.94736856925479,118.46315809233971,140.97894761542463,163.49473713850958,186.0105266615945,208.52631618467942,231.04210570776434,253.55789523084925,276.0736847539342,298.5894742770191,{"y":321.105263800104,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.4,32.568837305129534,36.73767461025908,40.90651191538861,45.07534922051815,49.244186525647685,53.41302383077722,57.58186113590676,61.7506984410363,65.91953574616583,70.08837305129538,74.2572103564249,78.42604766155445,{"y":82.59488496668399,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.4,28.56393908076923,28.72787816153846,28.89181724230769,29.05575632307692,29.219695403846153,29.383634484615385,29.547573565384614,29.711512646153846,29.875451726923078,30.039390807692307,30.20332988846154,30.367268969230768,{"y":30.53120805,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.4,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€321.11

Average Price Target€82.59

Lowest Price Target€30.53

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram Selvaraju

H.C. Wainwright

€34.89

Buy

19.50%

Upside

Reiterated

09/14/26

Analysts Are Bullish on These Healthcare Stocks: Genmab (GMAB), Medicus Pharma Ltd (MDCX)

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

08/12/26

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Definitive Healthcare Corp (NASDAQ: DH) and Atai Beckley N.V. (NASDAQ: ATAI)

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/11/26

Genmab: Buy Rating Backed by Pivotal Epkinly Data Conviction and Blockbuster Potential Across Key Oncology Programs

Yaron Werber

TD Cowen

€37.51

Buy

28.46%

Upside

Assigned

08/07/26

Analysts Offer Insights on Healthcare Companies: Alector (NASDAQ: ALEC), Genmab (NASDAQ: GMAB) and Xenon (NASDAQ: XENE)

James Gordon CFA

Barclays

―

Buy

―

Reiterated

08/07/26

Analysts Are Bullish on Top Healthcare Stocks: Genmab (GMAB), Sotera Health (SHC)

Charlie Haywood

Bank of America Securities

―

Buy

―

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Irhythm Technologies (NASDAQ: IRTC) and Editas Medicine (NASDAQ: EDIT)

Benjamin Jackson CFA

Jefferies

―

Buy

―

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Cytokinetics (NASDAQ: CYTK) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Judah Frommer

Morgan Stanley

€28.79→€30.53

Hold

4.56%

Upside

Reiterated

08/07/26

Morgan Stanley Reaffirms Their Hold Rating on Genmab A/S (0MGB)

Rajan Sharma

Goldman Sachs

€321.05

Buy

999.50%

Upside

Reiterated

08/07/26

Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)

Michael Schmidt

Guggenheim

€34.89→€36.64

Buy

25.47%

Upside

Reiterated

08/06/26

Genmab price target raised to $42 from $40 at GuggenheimGenmab price target raised to $42 from $40 at Guggenheim

Eva Fortea Verdejo

Wells Fargo

€34.89

Buy

19.50%

Upside

Assigned

06/29/26

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB) and Hinge Health, Inc. Class A (NYSE: HNGE)

Kalpit Patel

Wolfe Research

€27.91

Buy

-4.40%

Downside

Reiterated

06/14/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Dianthus Therapeutics (NASDAQ: DNTH) and Aurora Cannabis (NASDAQ: ACB)

Jonathan Chang

Leerink Partners

€29.66→€34.02

Buy

16.51%

Upside

Reiterated

10/13/25

Leerink Partners Reaffirms Their Buy Rating on Genmab (GMAB)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram Selvaraju

H.C. Wainwright

€34.89

Buy

19.50%

Upside

Reiterated

09/14/26

Analysts Are Bullish on These Healthcare Stocks: Genmab (GMAB), Medicus Pharma Ltd (MDCX)

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

08/12/26

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Definitive Healthcare Corp (NASDAQ: DH) and Atai Beckley N.V. (NASDAQ: ATAI)

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/11/26

Genmab: Buy Rating Backed by Pivotal Epkinly Data Conviction and Blockbuster Potential Across Key Oncology Programs

Yaron Werber

TD Cowen

€37.51

Buy

28.46%

Upside

Assigned

08/07/26

Analysts Offer Insights on Healthcare Companies: Alector (NASDAQ: ALEC), Genmab (NASDAQ: GMAB) and Xenon (NASDAQ: XENE)

James Gordon CFA

Barclays

―

Buy

―

Reiterated

08/07/26

Analysts Are Bullish on Top Healthcare Stocks: Genmab (GMAB), Sotera Health (SHC)

Charlie Haywood

Bank of America Securities

―

Buy

―

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Irhythm Technologies (NASDAQ: IRTC) and Editas Medicine (NASDAQ: EDIT)

Benjamin Jackson CFA

Jefferies

―

Buy

―

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Cytokinetics (NASDAQ: CYTK) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Judah Frommer

Morgan Stanley

€28.79→€30.53

Hold

4.56%

Upside

Reiterated

08/07/26

Morgan Stanley Reaffirms Their Hold Rating on Genmab A/S (0MGB)

Rajan Sharma

Goldman Sachs

€321.05

Buy

999.50%

Upside

Reiterated

08/07/26

Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)

Michael Schmidt

Guggenheim

€34.89→€36.64

Buy

25.47%

Upside

Reiterated

08/06/26

Genmab price target raised to $42 from $40 at GuggenheimGenmab price target raised to $42 from $40 at Guggenheim

Eva Fortea Verdejo

Wells Fargo

€34.89

Buy

19.50%

Upside

Assigned

06/29/26

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB) and Hinge Health, Inc. Class A (NYSE: HNGE)

Kalpit Patel

Wolfe Research

€27.91

Buy

-4.40%

Downside

Reiterated

06/14/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Dianthus Therapeutics (NASDAQ: DNTH) and Aurora Cannabis (NASDAQ: ACB)

Jonathan Chang

Leerink Partners

€29.66→€34.02

Buy

16.51%

Upside

Reiterated

10/13/25

Leerink Partners Reaffirms Their Buy Rating on Genmab (GMAB)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AMRXAmneal Pharmaceuticals

DNTHDianthus Therapeutics

ACHVAchieve Life Sciences

AHCOAdaptHealth

PMNProMIS Neurosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genmab

3 Months

Matt PhippsWilliam Blair

Success Rate

12/15 ratings generated profit

Average Return

+9.51%

Copying Matt Phipps's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +9.51% per trade.

1 Year

Jonathan ChangLeerink Partners

Success Rate

7/7 ratings generated profit

Average Return

+28.29%

Copying Jonathan Chang's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +28.29% per trade.

2 Years

Jonathan ChangLeerink Partners

Success Rate

7/7 ratings generated profit

Average Return

+56.69%

Copying Jonathan Chang's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +56.69% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GE91 Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GE91 has received 16 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. GE91 average Analyst price target in the past 3 months is 82.59.

Each month's total comprises the sum of three months' worth of ratings.

GE91 Financial Forecast

GE91 Earnings Forecast

Next quarter’s earnings estimate for GE91 is €0.33 with a range of €0.21 to €0.53. The previous quarter’s EPS was €0.43. GE91 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GE91 has Performed in-line its overall industry.

GE91 Sales Forecast

Next quarter’s sales forecast for GE91 is €1.06B with a range of €1.01B to €1.28B. The previous quarter’s sales results were €1.01B. GE91 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GE91 has Performed in-line its overall industry.

GE91 Stock Forecast FAQ

What is DE:GE91’s average 12-month price target, according to analysts?

Based on analyst ratings, Genmab A/S’s 12-month average price target is 82.59.

What is DE:GE91’s upside potential, based on the analysts’ average price target?

Genmab A/S has 182.86% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Genmab A/S a Buy, Sell or Hold?

Genmab A/S has a consensus rating of Strong Buy, which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is Genmab A/S’s share price target?

The average share price target for Genmab A/S is 82.59. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €321.11 ,and the lowest forecast is €30.53. The average share price target represents 182.86% Increase from the current price of €29.2.

What do analysts say about Genmab A/S?

Genmab A/S’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Genmab A/S?

To buy shares of DE:GE91, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Genmab (GE91) Stock Forecast & Price Target

GE91 Analyst Ratings

GE91 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Genmab

GE91 Analyst Recommendation Trends

GE91 Financial Forecast

GE91 Earnings Forecast

GE91 Sales Forecast

GE91 Stock Forecast FAQ

Detailed List of Analyst Forecasts